Selected research
Industry Research
Meningococcal Disease Drugs Industry Research Report 2026
Market perspective
The global Meningococcal Disease Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Meningococcal Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Meningococcal Disease Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Meningococcal Disease Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Meningococcal Disease Drugs include Yiling Pharmaceutical, SSY Group Limited, Apeloa Pharmaceutical Co.,Ltd., Novartis, Merck Sharp & Dohme, Lukang Pharmaceutical Co.,Ltd., Shandong Jincheng Pharmaceutical Group Co.,ltd., Pfizer and North China Pharmaceutical Company Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Meningococcal Disease Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Meningococcal Disease Drugs Market by Company
Yiling Pharmaceutical
SSY Group Limited
Apeloa Pharmaceutical Co.,Ltd.
Novartis
Merck Sharp & Dohme
Lukang Pharmaceutical Co.,Ltd.
Shandong Jincheng Pharmaceutical Group Co.,ltd.
Pfizer
North China Pharmaceutical Company Ltd.
Hebei Hejia Pharmaceutical Technology Group Co., Ltd
Harbin Pharmaceutical Group Co.,Ltd.
GlaxoSmithKline
Baiyunshan Pharmaceutical
Sanofi Pasteur
Meningococcal Disease Drugs Segment by Type
Injectable
Oral
Meningococcal Disease Drugs Segment by Application
Hospitals
Drugstores
Others
Meningococcal Disease Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Disease Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Meningococcal Disease Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Meningococcal Disease Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Meningococcal Disease Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injectable
- Oral
Applications
- Hospitals
- Drugstores
- Others
Companies covered
- Yiling Pharmaceutical
- SSY Group Limited
- Apeloa Pharmaceutical Co.,Ltd.
- Novartis
- Merck Sharp & Dohme
- Lukang Pharmaceutical Co.,Ltd.
- Shandong Jincheng Pharmaceutical Group Co.,ltd.
- Pfizer
- North China Pharmaceutical Company Ltd.
- Hebei Hejia Pharmaceutical Technology Group Co., Ltd
- Harbin Pharmaceutical Group Co.,Ltd.
- GlaxoSmithKline
- Baiyunshan Pharmaceutical
- Sanofi Pasteur
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Meningococcal Disease Drugs Market Size (2021-2032)
- 2.2.2 Global Meningococcal Disease Drugs Sales (2021-2032)
- 2.2.3 Global Meningococcal Disease Drugs Market Average Price (2021-2032)
- 2.3 Meningococcal Disease Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Injectable
- 2.3.3 Oral
- 2.4 Meningococcal Disease Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Drugstores
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Meningococcal Disease Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Meningococcal Disease Drugs Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Meningococcal Disease Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Meningococcal Disease Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Meningococcal Disease Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Meningococcal Disease Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Meningococcal Disease Drugs, Product Type & Application
- 3.8 Global Manufacturers of Meningococcal Disease Drugs, Established Date
- 3.9 Global Meningococcal Disease Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Yiling Pharmaceutical
- 4.1.1 Yiling Pharmaceutical Company Information
- 4.1.2 Yiling Pharmaceutical Business Overview
- 4.1.3 Yiling Pharmaceutical Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Yiling Pharmaceutical Meningococcal Disease Drugs Product Portfolio
- 4.1.5 Yiling Pharmaceutical Recent Developments
- 4.2 SSY Group Limited
- 4.2.1 SSY Group Limited Company Information
- 4.2.2 SSY Group Limited Business Overview
- 4.2.3 SSY Group Limited Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 SSY Group Limited Meningococcal Disease Drugs Product Portfolio
- 4.2.5 SSY Group Limited Recent Developments
- 4.3 Apeloa Pharmaceutical Co.,Ltd.
- 4.3.1 Apeloa Pharmaceutical Co.,Ltd. Company Information
- 4.3.2 Apeloa Pharmaceutical Co.,Ltd. Business Overview
- 4.3.3 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Product Portfolio
- 4.3.5 Apeloa Pharmaceutical Co.,Ltd. Recent Developments
- 4.4 Novartis
- 4.4.1 Novartis Company Information
- 4.4.2 Novartis Business Overview
- 4.4.3 Novartis Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis Meningococcal Disease Drugs Product Portfolio
- 4.4.5 Novartis Recent Developments
- 4.5 Merck Sharp & Dohme
- 4.5.1 Merck Sharp & Dohme Company Information
- 4.5.2 Merck Sharp & Dohme Business Overview
- 4.5.3 Merck Sharp & Dohme Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck Sharp & Dohme Meningococcal Disease Drugs Product Portfolio
- 4.5.5 Merck Sharp & Dohme Recent Developments
- 4.6 Lukang Pharmaceutical Co.,Ltd.
- 4.6.1 Lukang Pharmaceutical Co.,Ltd. Company Information
- 4.6.2 Lukang Pharmaceutical Co.,Ltd. Business Overview
- 4.6.3 Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Product Portfolio
- 4.6.5 Lukang Pharmaceutical Co.,Ltd. Recent Developments
- 4.7 Shandong Jincheng Pharmaceutical Group Co.,ltd.
- 4.7.1 Shandong Jincheng Pharmaceutical Group Co.,ltd. Company Information
- 4.7.2 Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview
- 4.7.3 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Product Portfolio
- 4.7.5 Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Developments
- 4.8 Pfizer
- 4.8.1 Pfizer Company Information
- 4.8.2 Pfizer Business Overview
- 4.8.3 Pfizer Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Pfizer Meningococcal Disease Drugs Product Portfolio
- 4.8.5 Pfizer Recent Developments
- 4.9 North China Pharmaceutical Company Ltd.
- 4.9.1 North China Pharmaceutical Company Ltd. Company Information
- 4.9.2 North China Pharmaceutical Company Ltd. Business Overview
- 4.9.3 North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Product Portfolio
- 4.9.5 North China Pharmaceutical Company Ltd. Recent Developments
- 4.10 Hebei Hejia Pharmaceutical Technology Group Co., Ltd
- 4.10.1 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Company Information
- 4.10.2 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview
- 4.10.3 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Product Portfolio
- 4.10.5 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Developments
- 4.11 Harbin Pharmaceutical Group Co.,Ltd.
- 4.11.1 Harbin Pharmaceutical Group Co.,Ltd. Company Information
- 4.11.2 Harbin Pharmaceutical Group Co.,Ltd. Business Overview
- 4.11.3 Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Product Portfolio
- 4.11.5 Harbin Pharmaceutical Group Co.,Ltd. Recent Developments
- 4.12 GlaxoSmithKline
- 4.12.1 GlaxoSmithKline Company Information
- 4.12.2 GlaxoSmithKline Business Overview
- 4.12.3 GlaxoSmithKline Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 GlaxoSmithKline Meningococcal Disease Drugs Product Portfolio
- 4.12.5 GlaxoSmithKline Recent Developments
- 4.13 Baiyunshan Pharmaceutical
- 4.13.1 Baiyunshan Pharmaceutical Company Information
- 4.13.2 Baiyunshan Pharmaceutical Business Overview
- 4.13.3 Baiyunshan Pharmaceutical Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Baiyunshan Pharmaceutical Meningococcal Disease Drugs Product Portfolio
- 4.13.5 Baiyunshan Pharmaceutical Recent Developments
- 4.14 Sanofi Pasteur
- 4.14.1 Sanofi Pasteur Company Information
- 4.14.2 Sanofi Pasteur Business Overview
- 4.14.3 Sanofi Pasteur Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Sanofi Pasteur Meningococcal Disease Drugs Product Portfolio
- 4.14.5 Sanofi Pasteur Recent Developments
5 Global Meningococcal Disease Drugs Market Scenario by Region
- 5.1 Global Meningococcal Disease Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Meningococcal Disease Drugs Sales by Region: 2021-2032
- 5.2.1 Global Meningococcal Disease Drugs Sales by Region: 2021-2026
- 5.2.2 Global Meningococcal Disease Drugs Sales by Region: 2027-2032
- 5.3 Global Meningococcal Disease Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Meningococcal Disease Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Meningococcal Disease Drugs Revenue by Region: 2027-2032
- 5.4 North America Meningococcal Disease Drugs Market Facts & Figures by Country
- 5.4.1 North America Meningococcal Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Meningococcal Disease Drugs Sales by Country (2021-2032)
- 5.4.3 North America Meningococcal Disease Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Meningococcal Disease Drugs Market Facts & Figures by Country
- 5.5.1 Europe Meningococcal Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Meningococcal Disease Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Meningococcal Disease Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Meningococcal Disease Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Meningococcal Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Meningococcal Disease Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Meningococcal Disease Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Meningococcal Disease Drugs Market Facts & Figures by Country
- 5.7.1 South America Meningococcal Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Meningococcal Disease Drugs Sales by Country (2021-2032)
- 5.7.3 South America Meningococcal Disease Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Meningococcal Disease Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Meningococcal Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Meningococcal Disease Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Meningococcal Disease Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Meningococcal Disease Drugs Sales by Type (2021-2032)
- 6.1.1 Global Meningococcal Disease Drugs Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Meningococcal Disease Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Meningococcal Disease Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Meningococcal Disease Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Meningococcal Disease Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Meningococcal Disease Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Meningococcal Disease Drugs Sales by Application (2021-2032)
- 7.1.1 Global Meningococcal Disease Drugs Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Meningococcal Disease Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Meningococcal Disease Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Meningococcal Disease Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Meningococcal Disease Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Meningococcal Disease Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Meningococcal Disease Drugs Value Chain Analysis
- 8.1.1 Meningococcal Disease Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Meningococcal Disease Drugs Production Mode & Process
- 8.2 Meningococcal Disease Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Meningococcal Disease Drugs Distributors
- 8.2.3 Meningococcal Disease Drugs Customers
9 Global Meningococcal Disease Drugs Analyzing Market Dynamics
- 9.1 Meningococcal Disease Drugs Industry Trends
- 9.2 Meningococcal Disease Drugs Industry Drivers
- 9.3 Meningococcal Disease Drugs Industry Opportunities and Challenges
- 9.4 Meningococcal Disease Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst